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Abstract
Inflammation is becoming increasingly recognized as an important contributor to Alzheimer’s disease (AD) pathogenesis.
As a part of the innate immune system, the complement cascade enhances the body’s ability to destroy and remove
pathogens and has recently been shown to influence Alzheimer’s associated amyloid and tau pathology. However, little
is known in humans about the effects of the complement system and genetic modifiers of AD risk like the ε4 allele of
apolioprotein E (APOE ε4) on AD pathobiology. We evaluated cerebrospinal fluid (CSF) protein levels from 267
individuals clinically diagnosed as cognitively normal, mild cognitive impairment, and AD. Using linear models,
we assessed the relationship between APOE ε4 genotype, CSF Complement 3 (C3), CSF amyloid-β (amyloid) and CSF
hyperphosphorylated tau (ptau). We found a significant interaction between APOE ε4 and CSF C3 on both CSF amyloid
and CSF ptau. We also found that CSF C3 is only associated with CSF ptau after accounting for CSF amyloid. Our results
support a conceptual model of the AD pathogenic cascade where a synergistic relationship between the complement
cascade (C3) and APOE ε4 results in elevated Alzheimer’s neurodegeneration and in turn, amyloid further regulates the
effect of the complement cascade on downstream tau pathology.
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Introduction
Converging experimental and human biomarker evidence
suggests that the immune system plays a critical role in
Alzheimer’s disease (AD) pathobiology. In rodent models
of AD, neuroinflammatory signals have been shown to
correlate with amyloid and hyperphosphorylated tau
(ptau) deposits as well as cognitive symptoms [23].
Observational studies in humans have shown that neuro-
inflammation, particularly the innate immune system,
contributes to and drives AD pathogenesis [14]. Genetic
studies in humans have identified a relationship between in-
flammatory and immune-associated genes and increased
risk for AD [18] and have suggested that immune-mediated
genes may contribute to Alzheimer’s pathogenesis [32].
Importantly, several studies have demonstrated that the ε4
allele of apolipoprotein (APOE ε4), the most common
genetic risk factor for AD, has an important role in immune
and inflammatory processes underlying Alzheimer’s neuro-
degeneration [6, 29]. Further, a recent study of epigenomic
signals in mice and humans has implicated regulatory
changes in immune response genes and immune-
regulatory genes in AD [13].
Recent work suggests an association between inflamma-
tory pathways, amyloid, and tau pathology. In mouse
models, Complement C1q has been shown to be neces-
sary for amyloid-β associated synaptotoxicity [15]. Using
microarray data from amyloid and tau transgenic mice,
immune gene expression has been shown to be tightly as-
sociated with amyloid plaques rather than neurofibrillary
tangles suggesting that amyloid dysmetabolism mediates
the influence of the immune system on tau pathology
[19]. Although several studies have examined the associ-
ation between inflammation and AD neurodegeneration
in humans, it is still unknown whether APOE ε4
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influences the relationship between inflammation
(specifically the complement cascade) and amyloid and
tau pathology.
Here, we investigated the relationship between APOE
ε4 and the complement system on amyloid and tau
pathology in AD. We evaluated cerebrospinal fluid
(CSF) measurements of the immune protein Complement
3 (C3) as well as amyloid β1-42 (amyloid) and ptau181p
(ptau), which are sensitive in vivo markers of clinical diag-
nosis, decline, and pathology in AD [8, 9, 24]. Low CSF
amyloid levels are associated with increased amyloid pla-
ques in the brain while high CSF ptau levels are associated
with increased ptau tangles in the brain [4, 9]. Low CSF
C3 has been associated with worsening cognitive decline
in mild cognitive impairment (MCI) [28] and improves
diagnostic accuracy when used alongside CSF amyloid and
tau [16]. We hypothesized that a statistical interaction be-
tween APOE ε4 and CSF C3 levels would be associated
with low CSF amyloid (suggesting increased intracranial
amyloid plaques) and elevated CSF ptau (suggesting
increased intracranial ptau tangles). Further, building on
prior work [15, 19], in a mediation analysis, we hypothe-
sized that CSF amyloid would ‘mediate’ the effect of CSF
C3 on CSF ptau.
Materials and methods
Participant description
This study utilized samples from cognitively normal
older adults (HC; n = 71), individuals diagnosed with
amnestic MCI (n = 110), and probable AD (n = 56) from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI),
which has been used in previously published studies
[10, 11]. Clinical severity of symptoms in the MCI and
AD groupings was measured using the Clinical Dementia
Rating Sum of Boxes (CDR-SB) [22] and Mini Mental
State Exam (MMSE) [12]. Diagnostic groupings were
assigned using the clinical judgment of each site’s clini-
cians along with cutoffs based on neuropsychological tests
[33]. Briefly, controls were required to have normal mem-
ory function on the Logical Memory II subscale of the
Weschler Memory Scale – Revised [31], an MMSE score
greater than 24, CDR total score equal to 0, and judgment
by a clinician that the individual did not have any signifi-
cant impairment in cognitive function or activities of daily
living. Individuals with MCI were required to have abnor-
mal memory function on the Logical Memory II subscale
of the Weschler Memory Scale – Revised, an MMSE
greater than 24, CDR total score equal to 0.5, and judg-
ment by a clinician that the individual’s general cognition
and functional performance was preserved enough that a
diagnosis of AD could not be made. Finally, individuals
with AD were required to have abnormal memory func-
tion on the Logical Memory II subscale of the Weschler
Memory Scale – Revised, an MMSE between 20 and 26,
CDR total score equal to 0.5 or 1.0, and judgment by
a clinician that the individual met NINCDS/ADRDA
criteria for probable AD [20]. Informed consent was
obtained from all individual participants included in
the study. For more information on the ADNI cohort,
see Additional file 1.
Biomarker measurements
CSF amyloid β1-42 and CSF ptau181p were measured using
the AlzBio3 Luminex xMAP immunoassay (Innogenetics,
Ghent, Belgium) according to previously described
methods [24]. This method utilizes monoclonal antibodies
specific for amyloid β1-42 and ptau181p that are chemically
bonded to color-coded beads along with analyte-specific
detector antibodies. Baseline CSF C3 levels were measured
using a separate multiplex immunoassay panel (Luminex
technology), developed by Rules Based Medicine (Myriad
RBM; Austin, Texas). CSF measurements in the immuno-
assay panel were processed and normalized according to
previously described methods [7, 26]. Briefly, C3 levels
were measured using the Myriad RBM Human Discovery-
MAP panel, which measures CSF protein levels for a
range of metabolic, lipid, inflammatory, and other AD-
relevant indicators. Myriad RBM used a Luminex 100 in-
strument for the measurements and analyzed the resulting
data using proprietary software. The ADNI staff checked
the distributions of analytes in this panel for normality by
using Box-Cox analyses, and when appropriate log10
transformed the data to achieve an approximately normal
distribution. APOE genotype was previously generated by
ADNI using DNA extracted by Cogenics (now Beckman
Coulter Inc.; Pasadena, California) from a 3 mL aliquot of
EDTA blood. APOE ε4 dosage was scored as count of ε4
allele (0, 1, or 2) in all analyses.
Statistical analysis
We used chi-squared and one-way ANOVA for demo-
graphic and biomarker summary statistics and univariate
assessments. Multivariate linear models were used to
assess all biomarker relationships, covarying for baseline
age, baseline CDR-SB, and sex.
We first tested for a statistical interaction between
CSF C3 levels and APOE ε4 dosage on CSF amyloid and
CSF ptau levels. Prior to our secondary analyses, we veri-
fied that there was an association between CSF amyloid
and CSF ptau levels.
Next, we evaluated two theoretical models by which
CSF C3 levels might modify CSF ptau levels. In Model A,
we tested whether CSF amyloid levels ‘mediate’ CSF ptau
levels by adding it to a baseline model in which CSF C3
levels predict CSF ptau levels. In Model B, we test whether
a statistical interaction between CSF C3 levels and CSF
amyloid levels significantly predict CSF ptau levels.
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All analyses were performed using R. Plots were made
using the ‘visreg’ package in R [5].
Results
Cohort description
Our cohort was balanced with respect to age, sex, and
CSF C3 levels as there were no significant differences by
diagnostic group (Table 1). There were significant
differences in baseline CDR-SB scores, MMSE scores,
APOE ε4 dosage, CSF amyloid, and CSF ptau.
An interaction between CSF C3 and APOE ε4 predicts CSF
amyloid and CSF ptau
We found a significant statistical interaction between
CSF C3 and APOE ε4 dosage on CSF amyloid levels
(β-coefficient = -56.2, standard error (SE) = 23.8, p-
value = 0.02) suggesting increased intracranial amyloid
pathology among individuals with elevated intracranial
C3 levels and increased number of APOE ε4 alleles
(Fig. 1). With this interaction term in the model, we
found a main effect of CSF C3 (β-coefficient = 61.3,
SE = 21.9, p-value = 5.55 × 10−3) and APOE ε4 dosage
(β-coefficient = -182.0, SE = 62.0, p-value = 3.69 × 10−3).
Similarly, we found a significant statistical interaction
between CSF C3 and APOE ε4 dosage on CSF ptau levels
(β-coefficient = 22.5, SE = 8.6, p-value = 9.44 × 10−3)
suggesting increased neurofibrillary pathology among in-
dividuals with elevated C3 levels and increased number of
APOE ε4 alleles (Fig. 2). With this interaction term in the
model, we found a main effect of APOE ε4 dosage (β-coef-
ficient = 65.4, SE = 22.4, p-value = 3.86 × 10−3) but not CSF
C3 (β-coefficient = -4.3, SE = 7.9, p-value = 0.59).
Amyloid statistically mediates the effect of CSF C3 on
CSF ptau
We assessed whether CSF amyloid influences the rela-
tionship between CSF C3 and CSF ptau by statistically
testing two theoretical models (illustrated in Fig. 3).
Model A proposes that amyloid mediates the effect of
CSF C3 on CSF ptau. Model B proposes that an inter-
action between CSF C3 and CSF amyloid alters CSF ptau
levels.
Full regression results from Models A and B (shown in
Fig. 3) are provided in Table 2. We first tested Model A.
We found that CSF C3 did not predict CSF ptau in
the baseline model (p = 0.35). When CSF amyloid
levels were added to the baseline model as a mediating
variable, CSF C3 was significantly associated with CSF
ptau (p = 0.04). Next we assessed Model B. In contrast to
Model A, we found that there was no statistical inter-
action between CSF C3 and CSF amyloid on CSF
ptau (p = 0.41).
Discussion
Among individuals with elevated intracranial C3 and in-
creased APOE ε4 dosage, we found clinical evidence of
elevated intracranial amyloid and neurofibrillary tangle
pathology. We also found statistical evidence that amyl-
oid mediates the effect of C3 on ptau pathology. Consid-
ered together, our results support a conceptual model of
the AD pathogenic cascade where a synergistic relation-
ship between the complement cascade (C3) and APOE
ε4 results in elevated Alzheimer’s associated pathology
and in turn, amyloid further regulates the effect of the
complement cascade on ptau pathology (Fig. 4). These
results suggest that a combination of inflammatory and
pathologic biomarkers may help elucidate the neurode-
generative process underlying clinical AD.
Building on prior genetic evidence implicating a
relationship between APOE and immune dysfunction,
we found signs of elevated Alzheimer’s pathology in the
presence of both APOE ε4 and elevated complement
activation indicating that genetic propensity and inflam-
mation may act synergistically to accelerate amyloid and
tau pathology. In the presence of the statistical inter-
action, we found no effect of C3 on ptau suggesting that
APOE may play an important role in influencing the
relationship between inflammation and tau pathology.
Interestingly, even with the interaction term in place, we
found a significant effect of C3 on amyloid indicating
that the complement cascade could influence amyloid
pathology via both APOE-dependent and APOE-inde-
pendent mechanisms. Additional experimental work will
be required to delineate the precise mechanistic relation-
ship between complement activation, APOE, amyloid
and tau pathology.
Building on empirical research from prior studies
[15, 19], our mediation analyses suggest that amyloid
may influence the relationship between C3 and ptau.
These results support the hypothesis that amyloid dysme-
tabolism regulates downstream pathological processes via
Table 1 Demographic, genetic, and biomarker data summarized
by diagnostic group
NC MCI AD
N 71 110 56 P-value
Age (Mean ± SE) 76.5 ± 0.7 75.6 ± 0.7 74.9 ± 1.0 0.19
Sex (M/F) 36/35 72/38 30/26 0.11
CDR-SB (Mean ± SE) 0.04 ± 0.02 1.55 ± 0.09 4.13 ± 0.20 <0.001
APOE ε4 Dose (0/1/2) 56/14/1 47/49/14 17/25/14 <0.001
CSF amyloid β1-42
(Mean ± SE)
209.2 ± 6.2 158.6 ± 4.7 139.3 ± 4.4 <0.001
CSF ptau181p
(Mean ± SE)
25.5 ± 1.7 36.2 ± 1.5 43.0 ± 2.6 <0.001
CSF C3 (Mean ± SE) −2.56 ± 0.02 −2.57 ± 0.02 −2.58 ± 0.02 0.53
SE standard error, M male, F female, CDR-SB clinical dementia rating sum of
boxes score, MMSE mini mental state exam, NC normal control, MCI mild
cognitive impairment, AD Alzheimer’s Disease
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inflammatory mechanisms. Recent work has shown that
inflammatory processes are required for amyloid related
synaptotoxicity [15] and other work has shown that amyl-
oid can incite an inflammatory response [27] and specific-
ally activate the complement cascade [1]. Taken together,
our findings draw attention to the role of C3 in
combination with amyloid and APOE as a potential regu-
lator of downstream pathology.
Our findings suggest that a pro-inflammatory environ-
mental milieu alters AD pathology in conjunction with
genotype. This work further illustrates that inflammatory
biomarkers along with genetic information may predict
Fig. 1 CSF amyloid versus CSF C3 by APOE ε4 dosage. CSF amyloid levels are plotted against CSF C3 levels by APOE ε4 dosage. C3 levels are quality
controlled and transformed as described in [26]. Non-carriers of the APOE ε4 allele (blue) have the highest level of amyloid in CSF, reflecting lower levels
of amyloid pathology in the brain, and display a positive slope. Carriers of one copy of the APOE ε4 allele (green) have intermediate levels of amyloid
and display an approximately flat slope. Carriers of two copies of the APOE ε4 allele (red) have the lowest levels of CSF amyloid, suggesting the highest
levels of amyloid pathology in the brain, and display a negative slope. The plotted points are partial residuals with 95 % confidence bands provided
in shading
Fig. 2 CSF ptau versus CSF C3 by APOE ε4 dosage. CSF ptau levels are plotted against CSF C3 levels by APOE ε4 dosage. C3 levels are quality
controlled and transformed as described in [26]. Non-carriers of the APOE ε4 allele (blue) have the lowest levels of ptau and display a slightly
negative slope. Carriers of one copy of the APOE ε4 allele (green) have intermediate levels of ptau and display a modestly positive slope. Carriers
of two copies of the APOE ε4 allele (red) have the highest levels of ptau and display a strongly positive slope. The plotted points are partial
residuals with 95 % confidence bands provided in shading
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increased risk for AD [32] and other neurodegenerative
disorders with genetic and immune components [21].
Clinically, this is important because it suggests that
modifying specific components of the innate immune
system or their downstream signaling pathways may
serve as a target, which could ameliorate AD pathology.
In addition to amyloid and tau metabolism and
clearance, these results, in combination with prior
studies [2, 17, 25, 30], underscore the importance of
targeting inflammatory (specifically the complement
cascade) processes for AD prevention.
Our study benefits from its use of a well-established,
thoroughly characterized cohort of AD, MCI and cogni-
tively normal healthy controls. In addition, our study
benefits from using CSF, which is a biologically proxim-
ate measure of disease status and progression [3, 4]. A
limitation of our study is its observational nature, which
prevents us from determining a causative relationship.
We cannot determine whether C3 causes, results from,
or merely correlates with amyloid deposition. The
specific biological mechanisms by which C3 and APOE
ε4 influence ptau and amyloid remain to be determined.
Fig. 3 Two possible models for the relationship between C3, amyloid, and ptau. Two possible models for the effects of C3, amyloid β, and APOE
ε4 on ptau are illustrated as A and B. Solid arrows represent main effects of each variable and dotted arrows represent the interaction effect of
two variables, all assessed in multivariate linear models which included age, sex, and CDR-SB score as covariates. Results for the two illustrated
models are in Table 2. a Model A hypothesizes that C3’s effect on ptau will be mediated by amyloid. Roman numerals represent the following
effects: (I) direct effect of C3 to predict ptau and (II) the hypothesized mediating effect of amyloid when added to the model in (I). b Model B
suggests an alternate relationship whereby C3 and amyloid act synergistically to alter ptau. Roman numeral (I) corresponds to a hypothesized
statistical interaction between C3 and amyloid to predict ptau levels
Table 2 Results for two proposed models of C3’s effect on ptau
in which amyloid mediates the effect of C3 on ptau (Model A)
and in which C3 and amyloid act synergistically on ptau (Model B)
Model Analysis Outcome Variable Estimate ± SE P-value
Model A I CSF ptau Age −0.32 ± 0.2 0.05
Sex −2.41 ± 2.3 0.29
CDR-SB 3.35 ± 0.6 7.25 × 10−8
C3 6.10 ± 6.5 0.35
II CSF ptau Age −0.22 ± 0.1 0.14
Sex −1.15 ± 2.05 0.58
CDR-SB 1.67 ± 0.6 5.01 × 10−3
C3 12.11 ± 5.9 0.04
CSF amyloid −0.14 ± 0.02 4.97 × 10−12
Model B I CSF ptau Age −0.25 ± 0.15 0.10
Sex −1.11 ± 2.1 0.59
CDR-SB 1.70 ± 0.6 4.47 × 10−3
C3 27.7 ± 19.6 0.16
CSF amyloid −0.38 ± 0.3 0.19
C3:CSF
amyloid
−0.09 ± 0.1 0.41
SE standard error
An illustration of the two models is provided in Fig. 3. Estimates are β
estimates from a multiple regression model which included age, sex, and
baseline CDR-SB score as covariates
Fig. 4 Proposed biological model for the relationships between C3,
APOE ε4, and amyloid on ptau. A proposed model for the relationships
between C3, APOE ε4, and amyloid on ptau based on results from our
statistical analyses. Solid arrows represent main effects of each variable
and dotted arrows represent the interaction effect of two variables, all
assessed in multivariate linear models which included age, sex,
and CDR-SB score as covariates. Roman numerals represent the
following effects: (I) interaction effect of C3 and APOE ε4 on amyloid (II)
interaction effect of C3 and APOE ε4 on ptau, and (III) the effect of C3
on ptau, which is mediated by amyloid
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Our results will require follow-up in a larger, independent
population-based cohort to determine the generalizability
of this finding to diverse communities. Finally, our study
highlights the need for future longitudinal studies that can
directly test the causal effects suggested by our correlative
analyses.
Conclusion
In summary, we found a statistical interaction between
elevated C3 and APOE ε4 dosage on biomarkers indica-
tive of elevated amyloid and tau pathology. Further, our
mediation analyses indicate that C3 is associated with
ptau only after adjusting for amyloid suggesting that
amyloid may mediate the relationship between inflam-
mation and tau pathology. Our findings underscore the
importance of APOE ε4 in regulating the putative effects
of C3 on both amyloid and ptau. More generally, this
study highlights the importance of the innate immune
system in modulating levels of the pathological proteins
most associated with AD and its relevance as a biomarker
and potential therapeutic target.
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